Patents Examined by Zohreh A. Fay
  • Patent number: 11058629
    Abstract: Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection, in particular analgesics such as buprenorphine.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: July 13, 2021
    Assignee: Piedmont Animal Health Inc.
    Inventors: Douglas I. Hepler, Gail L. Dempsey, Dorothea Erxleben
  • Patent number: 11052107
    Abstract: The present invention provides solid compositions of amorphous calcium carbonate (ACC) and a polyphosphate, bisphosphonate or pharmaceutical salts thereof as a stabilizer. Said stabilizers stabilizes the ACC and prevent crystallization to crystalline calcium carbonate ((?( (?) for a long period of time, even in an aqueous suspension. The invention further provides pharmaceutical composition comprising the solid ACC compositions as well their use in treating of certain diseases and conditions.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 6, 2021
    Assignee: AMORPHICAL LTD.
    Inventors: Yosef Ben, Yigal Dov Blum, Hagay Moshe, Ben Ashkenazi
  • Patent number: 11045431
    Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: June 29, 2021
    Assignee: ZeaVision LLC
    Inventor: Dennis L. Gierhart
  • Patent number: 11033576
    Abstract: The present invention provides compositions comprising amorphous calcium carbonate (ACC), suitable to being administered by inhalation, and methods for their use in treating ACC-responsive diseases and conditions. Further provided are ACC compositions suitable for buccal or sublingual administration.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: June 15, 2021
    Assignee: AMORPHICAL LTD.
    Inventors: Yosef Ben, Yigal Dov Blum
  • Patent number: 11026869
    Abstract: The present invention relates to novel process for making oil-in-water nanoemulsions. The oil phase contains oil selected from the group consisting of triglyceride oil and/or petrolatum and a C8 to C16 fatty acid just be added during preparation; and the aqueous phase contains specific N-acyl derivatives of carboxylic amino acid as primary emulsifier.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: June 8, 2021
    Assignee: CONOPCO, INC.
    Inventors: David John Lang, Congling Quan
  • Patent number: 11026918
    Abstract: A pharmaceutical composition for aerosol administration and method of preventing or treating a pulmonary disease or condition in a subject with a SphK1 inhibitor are provided.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: June 8, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Anantha Harijith, Viswanathan Natarajan, Roberto F. Machado, Jeffrey Jacobson
  • Patent number: 11021469
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 1, 2021
    Assignees: LOYOLA UNIVERSITY OF CHICAGO, Board of Regents, The University of Texas System
    Inventors: Daniel Paul Becker, Tahirah K. Heath, Cory Reidl, Walter Fast
  • Patent number: 11020355
    Abstract: A method of encapsulating cannabis-derived compounds in nanosized phospholipid vesicles is disclosed. A Cannabis sativa-derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa-derived substances.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: June 1, 2021
    Assignee: NuVessl, Inc.
    Inventors: Tanya Rhodes, Deborah Duffey
  • Patent number: 11020390
    Abstract: The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: June 1, 2021
    Assignee: UNICHEM LABORATORIES LTD
    Inventors: Dhananjay Sathe, Bijay Kumar Padhi, Pravin Kumar Maurya
  • Patent number: 11013249
    Abstract: It is provided a composition for controlled-release of volatile compounds comprising at least one poly(ethylene glycol) (PEG) polymer and one or more volatile compounds, the composition used for preserving food when incorporated in a food packaging. The volatile compounds are antimicrobial compounds such as allyl isothiocyanate (AITC), diacetyl, cinnamaldehyde, thymol, carvacrol and a combination thereof. The composition can comprise a blend of two or more PEG polymers of different molecular weights and/or a mixture of poly(lactic acid) (PLA) and poly(ethylene oxide) (PEO).
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 25, 2021
    Inventors: Loong-Tak Lim, Wenjing Wang, Wenyu Huang
  • Patent number: 10987352
    Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: April 27, 2021
    Assignee: NICOX OPHTHALMICS, INC
    Inventors: Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
  • Patent number: 10980818
    Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: April 20, 2021
    Assignee: SUN PHARMA GLOBAL FZE
    Inventors: Lyle M Bowman, Kamran Hosseini
  • Patent number: 10973758
    Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: April 13, 2021
    Assignee: O.D. Ocular Discovery Ltd.
    Inventor: Moshe Rogosnitzky
  • Patent number: 10959915
    Abstract: The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that a coating processing for the easy-to-take property is simply performed by using a gelling agent in a dry process, without going through a wet condition, the easy-to-take solid preparation and the like.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 30, 2021
    Assignee: DAICEL CORPORATION
    Inventors: Momoko Hamasaki, Anan Sakaguchi, Tomohito Okabayashi, Naohiro Hashikawa, Takahiro Hiramura
  • Patent number: 10959916
    Abstract: The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that an outer layer-forming processing to provide an easy-to-take property is simply performed in a dry process without going through a wet condition so as to make the formed outer layer thicker; the easy-to-take solid preparation and the like.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 30, 2021
    Assignee: DAICEL CORPORATION
    Inventors: Momoko Hamasaki, Anan Sakaguchi, Tomohito Okabayashi, Takahiro Hiramura
  • Patent number: 10933000
    Abstract: An aluminum-free antiperspirant/deodorant composition in the form of stick, cream, or flowable gel includes a carrier that includes a polyhydric alcohol or is a mixture of a polyhydric alcohol and water; a thickening agent including a C14-22 fatty acid salt; and an antiperspirant active and optionally a film-forming polymer dispersed in the carrier. The antiperspirant active is primarily a zinc-based antiperspirant active.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 2, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Peter Hilliard, Jr., Sharon Kennedy, Darrick Carlone, Cristina Bielli, Richard Adams
  • Patent number: 10932995
    Abstract: The invention relates to a dental composition comprising a resin matrix, a filler matrix in an amount of at least 25 wt. % with respect to the weight of the dental composition, an initiator system, the resin matrix comprising polymerizable monomer(s) comprising two (meth)acrylate moieties connected to a brominated resorcinol, catechol, tyrosol, benzoic acid or phenol moiety. The invention relates also to a dental milling block comprising this composition in its hardened stage.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 2, 2021
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Adrian S. Eckert, Karsten Dede, Christoph H. Thalacker, Gioacchino Raia
  • Patent number: 10933021
    Abstract: The present invention relates to dosage forms of gallium complexes suitable for oral delivery and methods of preparation thereof. Such dosage forms are useful for the treatment of diseases, including, but not limited to, cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: March 2, 2021
    Assignee: Altum Pharmaceuticals Inc.
    Inventors: Rickey Roy Rhinebarger, Gina G. Stetsko
  • Patent number: 10918631
    Abstract: The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: February 16, 2021
    Assignee: NewMarket Pharmaceuticals LLC
    Inventors: Mark Ridall, David Rock
  • Patent number: 10912752
    Abstract: The invention relates to compositions and devices which include an osmolytic agent, in particular a betaine or carnitine compound, for reducing ocular discomfort associated with various diseases or conditions, in particular diseases or conditions associated with high tear film tonicity. The invention also relates to methods of treating or preventing various diseases or conditions using compositions and devices of the invention.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: February 9, 2021
    Assignee: Brien Holden Vision Institute Limited
    Inventor: Qian Garrett